Sasheen Hamilton, Ph.D., M.A.

Sasheen Hamilton, Ph.D., M.A.
Postdoctoral Fellow (CRTA)

Dr. Hamilton is focusing on protein engineering to generate novel imaging and therapeutic agents for hepatocellular carcinoma.

Areas of Expertise

1) biochemistry, 2) biophysical oncology, 3) molecular biology

Contact Info

Sasheen Hamilton, Ph.D., M.A.
Center for Cancer Research
National Cancer Institute
Building 10, Room 1B55
Bethesda, MD 20892
Ph: 240-858-3062
sasheen.hamilton@nih.gov

Selected Recent Publications

  1. Shafirstein G, Bellnier DA, Oakley E, Hamilton S, Habitzruther M, Tworek L, Hutson A, Spernyak JA, Sexton S, Curtin L, Turowski SG, Arshad H, Henderson B.
    Br J Cancer. 119(10): 1191-1199, 2018. [ Journal Article ]
  2. Shafirstein G, Bellnier D, Oakley E, Hamilton S, Potasek M, Beeson K, Parilov E.
    Cancers. 9(2): 12, 2017. [ Journal Article ]
  3. Bianco PR, Pottinger S, Tan HY, Nguyenduc T, Rex K, Varshney U.
    26(2): 227-241, 2017. [ Journal Article ]
  4. Tan HY, Wilczek LA, Pottinger S, Manosas M, Yu C, Nguyenduc T, Bianco PR.
    Protein Sci. 26(4): 700-717, 2017. [ Journal Article ]

Dr. Hamilton was born and raised in the beautiful Caribbean island of Jamaica. Dr. Hamilton migrated to the USA following completion of high school to pursue a college education. Dr. Hamilton commenced her scientific training at Cornell University where she received her Bachelor’s degree in Biological Science. Her undergraduate training led to her desire to understand the basic molecular and cellular processes where she earned her Master in Biochemistry at the University at Buffalo.  Following her Master’s project, Dr. Hamilton wanted to apply her knowledge from basic research to a path that was more translational, with clinical orientation. This led to her enrollment in the Biophysical Oncology Ph.D. program at Roswell Park Comprehensive Cancer Center. Dr. Hamilton has now joined Dr. Escorcia's lab where she will apply her diverse knowledge from basic to translational research to perform protein engineering to implement novel imaging and therapeutic agents for hepatocellular carcinoma.